COGSTATE LTD — Capital/Financing Update 2015

May 11, 2015

ASX ANNOUNCEMENT 12 MAY 2015

==> picture [172 x 48] intentionally omitted <==

PRIVATE PLACEMENT RAISES $2 MILLION CAPITAL DR ALAN FINKEL AO APPOINTED TO COGSTATE BOARD

Cogstate Ltd (ASX:CGS) is pleased to announce the appointment of a new non-executive Board member, Dr Alan Finkel AO. In conjunction with the appointment, Cogstate will make a Placement of 8 million ordinary shares to an entity controlled by Dr Finkel, at $0.25 per share, raising $2 million of additional capital.

Dr Finkel is Chancellor of Monash University and President of the Australian Academy of Technological Sciences and Engineering. He is a respected neuroscientist, electrical engineer, entrepreneur and philanthropist.

Highlights of Dr Finkel’s business career include founding Axon Instruments, a California-based, ASXlisted supplier of electronic and robotic instruments used in neuroscience research and pharmaceutical drug development. Axon Instruments was acquired by US based Molecular Devices Corporation for $140 million in 2004, after which Dr Finkel took on the role of Chief Technology Officer at Molecular Devices.

He has also served as Chief Technology Officer for Better Place Australia, and is the Executive Chairman of Stile Education, an education technology company based in Melbourne. He is also Executive Publisher of Cosmos Magazine.

Dr Finkel has served as the Chancellor of Monash University since January 2008 and has an extensive and varied career in academia, including neuroscience research, business and related philanthropic initiatives. He completed his doctoral studies in electrical engineering at Monash University, and served as a neuroscience research fellow at the John Curtin School of Medical Research at the Australian National University.

“We are absolutely delighted to welcome Dr Finkel, a long time investor and supporter of the Company, to the Board of Cogstate. Alan is an Australian with extensive experience running a neuroscience based technology company in the USA; making him uniquely qualified to understand a business like Cogstate. Alan has a passion for technology and science, he is widely respected, and he brings a unique blend of skills and experience spanning technology, business and neuroscience, which is highly complementary to the Cogstate business. His appointment and support of Cogstate is an excellent endorsement of the opportunity that Cogstate has to continue to evolve our business and stand out as an international leader in cognition testing,” said Brad O’Connor, Chief Executive of Cogstate.

The shares issued under the Placement will be issued under the Company’s 15% placement capacity under ASX Listing Rule 7.1. The $2 million capital raised will be used to provide additional working capital.

For further information contact:

Brad O’Connor Cogstate Chief Executive Officer +61 3 9664 1300 or 0411 888 347 boconnor@cogstate.com

MORE ABOUT DR ALAN FINKEL AO

Dr Finkel received his Bachelor of Engineering in 1976 and a Doctorate in Electrical Engineering from Monash University in 1981, following which he served two years as a neuroscience research fellow at the John Curtin School of Medical Research, located at the Australian National University.

In 1983, Dr Finkel founded Axon Instruments, a California-based, ASX listed company that made precision scientific instruments used at universities for the elucidation of the fundamental molecular mechanisms underlying neurological health and disease states, and used at pharmaceutical companies for discovery and safety testing of new medicines. In 2004, Axon was acquired by US firm Molecular Devices Corporation and since then Dr Finkel has enjoyed a varied business career that includes property development and a period in electric vehicle charge network provision.

In 2005, Dr Finkel was appointed to the Clunies Ross Foundation Board of Governors and in 2006 he was elected as a Fellow of the Australian Academy of Technological Science and Engineering. In 2014 he was also appointed as an Officer of the Order of Australia for distinguished service to science and engineering, and to tertiary education administration, as an advocate for the protection of children, and to philanthropy.

Dr Finkel has been Chancellor of Monash University since 2008 and President of the Australian Academy of Technological Sciences and Engineering (ATSE) since 2013. As President of ATSE, Dr Finkel is an Ex Officio member of the Board of Directors of the Crawford Fund.

In 2010 and 2011 Dr Finkel served as the Chief Technology Officer for Better Place Australia, a company established to provide clean energy to run Australia’s future fleet of electric cars. He is the chairman of the Australian Centre of Excellence for All-Sky Astrophysics and the Executive Chairman of Stile Education, an education technology company based in Melbourne. He is also co-founder and Executive Publisher of Cosmos Magazine, a leading literary science magazine that covers the latest discoveries and breakthroughs in science.

Dr Finkel established the Australian Course in Advanced Neuroscience to provide advanced training to early career neuroscientists. He also leads a secondary school science program named STELR, administered by ATSE, which is currently running in nearly 450 secondary schools around Australia.

ABOUT COGSTATE

Cogstate Ltd (ASX:CGS) is a leading cognitive science company focused on optimising the measurement of cognition to guide decision-making. Cogstate commercializes rapid, reliable, and highly sensitive computerized cognitive tests for clinical trials, academic research and healthcare.

In its Clinical Trials business, Cogstate provides both novel technologies and expert professional services for clinical research programs seeking to demonstrate a drug’s impact on cognition. Delivering solutions spanning the continuum from study design to final statistical analysis, Cogstate’s latest Clinical Trials offering, Precision Recruitment™ is a powerful solution based on an online prescreening portal to accelerate the identification and engagement of qualified candidates for clinical trials in high-need indications such as Alzheimer’s disease.